{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xuzhang W"],"funding":["Shanghai Municipal Health Commission","collaborative innovation center for cardiovascular disease translational medicine","science and technology commission of shanghai municipality","shanghai chest hospital","National Natural Science Foundation of China","natural science foundation of shanghai","program of shanghai academic research leader","Clinical Research Plan of SHDC","national key research and development program of china"],"pagination":["17588359231156387"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9989452"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15"],"pubmed_abstract":["Background
Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO) resistance in advanced non-small-cell lung cancer (NSCLC), especially in personalized therapies for patients with different oligoprogressive patterns.Methods
Based on European Society for Radiotherapy and Oncology/European Organization for Research and Treatment of Cancer consensus, metastatic NSCLC patients with cancer progression after IO resistance were divided into four patterns, repeat oligoprogression (REO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (INO, oligoprogression "],"journal":["Therapeutic advances in medical oncology"],"pubmed_title":["Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC."],"pmcid":["PMC9989452"],"funding_grant_id":["17431906103","82072564","16CR3005A","TM202112","SHDC2020CR5001","YJXT20190209","22XD142280","20ZR1452000","CCTS202204","YJXT20190105","2016YFC1303300","82030045","2022XD029","19411950500","82241227"],"pubmed_authors":["Shen L","Li Z","Huang H","Lu S","Xuzhang W","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.","description":"Background
Oligoprogressive disease is recognized as the overall umbrella term; however, a small number of progressions on imaging can represent different clinical scenarios. This study aims to explore the optimal treatment strategy after immunotherapy (IO) resistance in advanced non-small-cell lung cancer (NSCLC), especially in personalized therapies for patients with different oligoprogressive patterns.Methods
Based on European Society for Radiotherapy and Oncology/European Organization for Research and Treatment of Cancer consensus, metastatic NSCLC patients with cancer progression after IO resistance were divided into four patterns, repeat oligoprogression (REO, oligoprogression with a history of oligometastatic disease), induced oligoprogression (INO, oligoprogression ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-05-13T14:27:25.759Z","creation":"2025-02-19T03:26:20.967Z"},"accession":"S-EPMC9989452","cross_references":{"pubmed":["36895853"],"doi":["10.1177/17588359231156387"]}}